Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could pesticides fuel brain tumor aggression?

NCT ID NCT07788430

Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study investigates whether exposure to pesticides influences how aggressive a type of brain tumor called glioblastoma is and how well patients respond to treatment. Researchers will collect urine, hair, and optional blood samples from 120 adults newly diagnosed with glioblastoma, along with a detailed questionnaire about their pesticide exposure. Participants will then be followed for about three years to track tumor progression and survival. The goal is to see if there is a link between pesticide exposure and the tumor's behavior.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Biological sample collection (urine, hair, optional blood) and a self-reported questionnaire on pesticide exposure
What this could lead to
If a link is found, this could help identify patients at higher risk and guide future prevention or monitoring strategies.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Results may be limited by the accuracy of self-reported exposure and the relatively small number of participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Patient newly diagnosed with IDH wild-type GBM * 2\. Age \>18 years old at the time of study entry * 3\. Patient who have not yet started the treatment for GBM (by, where applicable, concomitant radiochemotherapy or chemotherapy in combination with targeted therapy) * 4\. Patient having signed an informed consent form prior to any study-related procedures * 5\. Patient able to participate and willing to comply with the study procedures * 6\. Patient affiliated to a Social Health Insurance in France Exclusion Criteria: * 1\. Any condition contra-indicating sampling procedures required by the protocol. * 2\. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure * 3\. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioblastoma IDH (isocitrate dehydrogenase) wildtype are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glioblastoma IDH (isocitrate dehydrogenase) wildtype

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institut Universitaire du Cancer de Toulouse - Oncopole

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.